{
    "clinical_study": {
        "@rank": "161589", 
        "arm_group": [
            {
                "arm_group_label": "Vaccine group", 
                "description": "TB vaccine GSK 692342 (M72/AS01E) administered on study TB-018"
            }, 
            {
                "arm_group_label": "Placebo Comparator", 
                "description": "Placebo administered on study TB-018"
            }
        ], 
        "biospec_descr": {
            "textblock": "Specimens for this sub-study are collected from an interventional Phase 2 study (TB-018 see\n      NCT 01755598) and later analyzed for correlates of risk to tuberculosis.\n\n      PBMC/Plasma; Whole Blood cell count; Intracellular RNA"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "This is an independent optional sub-study parallel to TB-018 (NCT01755598) in which\n      biological samples will be collected for future investigations on biological correlates,\n      markers or prognostic factors for TB disease.  Subjects who consent to enroll in TB-018, \"A\n      phase IIb, double-blind, randomised, placebo-controlled study to evaluate the efficacy,\n      safety and immunogenicity of GSK Biologicals' candidate tuberculosis (TB) vaccine GSK 692342\n      (M72/AS01E) against TB disease, in healthy adults aged 18-50 years, living in a TB endemic\n      region\", (see NCT 01755598) will be asked to participate in this sub-study.  Subjects\n      enrolled in TB-018 who also consent to C-041-972 will be followed according to the TB-018\n      protocol but will have additional blood samples collected for the sub-study."
        }, 
        "brief_title": "Substudy of Protocol TB-018 (NCT01755598): Collection and Storage of Biological Samples for Evaluation of Correlates of TB (C-041-972)", 
        "completion_date": {
            "#text": "August 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Tuberculosis", 
        "condition_browse": {
            "mesh_term": "Tuberculosis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        To be eligible for this sub-study, subjects must be enrolled in TB-018 and provide\n        separate written informed consent for C-041-972.  See NCT 01755598 for inclusion criteria\n        into TB-018.\n\n        Exclusion criteria:\n\n        To be eligible for this sub-study, subjects must be enrolled in TB-018 and provide\n        separate written informed consent for C-041-972.  See NCT 01755598 for exclusion criteria\n        into TB-018."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Subjects who have consented to participate in TB-018 will be approached for participation\n        in this sub-study. Subjects who have consented to participate in TB-018 are not required\n        to participate in this sub-study."
            }
        }, 
        "enrollment": {
            "#text": "3506", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02097095", 
            "org_study_id": "C-041-972"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Correlates of risk", 
            "TB", 
            "Tuberculosis", 
            "Sub-study", 
            "TB-018"
        ], 
        "lastchanged_date": "March 24, 2014", 
        "number_of_groups": "2", 
        "official_title": "Substudy of GSK Protocol TB-018: Collection and Storage of Biological Samples for Evaluation of Correlates of Tuberculosis", 
        "overall_official": {
            "affiliation": "Aeras", 
            "last_name": "Bernard Landry, MS", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "South Africa: Medicines Control Council", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Additional blood samples will be collected from participants that have agreed to be in this sub-study of TB-018 (NCT01755598).", 
            "measure": "Collect and store biological samples for future use to evaluate potential biological markers correlated to the risk for tuberculosis.", 
            "safety_issue": "No", 
            "time_frame": "36 months in parallel with main study TB-018 (NCT01755598)."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02097095"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Collect and store biological samples for future use to evaluate immune correlates of protection from tuberculosis in subjects vaccinated with GSK 692342 (M72/AS01E).", 
            "safety_issue": "No", 
            "time_frame": "36 months in parallel with main study TB-018 (NCT01755598)."
        }, 
        "source": "Aeras", 
        "sponsors": {
            "collaborator": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Aeras", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2014", 
        "study_design": "Observational Model: Cohort", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}